In vitro assessment of CI-934--a new quinolone derivative.
CI-934 is a new broad-spectrum fluoroquinolone. We have studied its in vitro activity against 203 bacteria and compared it with ciprofloxacin, enoxacin, ampicillin, cefuroxime, cefotaxime, gentamicin, vancomycin and erythromycin. Against Gram-negative pathogens CI-934 showed broad-spectrum activity comparable to enoxacin. Of more interest is its superior activity against Gram-positive bacteria, especially Streptococcus pneumoniae and enterococci. This was further studied by observing its activity in comparison with ampicillin in in vitro kinetic studies. CI-934 was either equally or more rapidly bactericidal than ampicillin at concentrations of 1, 4, and 16 X MIC. On the basis of these findings further in vivo studies appear justified.
Finch
R
R
Martin
J
J
Pilkington
R
R
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002439:Cefotaxime / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D015365:Enoxacin; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology; D007700:Kinetics; D009287:Naphthyridines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D013291:Streptococcus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D009287:Naphthyridines; D011804:Quinolines; D015365:Enoxacin; D002939:Ciprofloxacin; D004917:Erythromycin; D014640:Vancomycin; C047718:CI 934; D002439:Cefotaxime; D002444:Cefuroxime